ZA200610474B - Compositions and methods for treating inflammatory disorders - Google Patents

Compositions and methods for treating inflammatory disorders

Info

Publication number
ZA200610474B
ZA200610474B ZA200610474A ZA200610474A ZA200610474B ZA 200610474 B ZA200610474 B ZA 200610474B ZA 200610474 A ZA200610474 A ZA 200610474A ZA 200610474 A ZA200610474 A ZA 200610474A ZA 200610474 B ZA200610474 B ZA 200610474B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
inflammatory disorders
treating inflammatory
treating
Prior art date
Application number
ZA200610474A
Inventor
Olga Ignatovich
Rudolf De Wildt
Benjamin Woolven
Steven Grant
Philip Jones
Amrik Basran
Neil Brewis
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2003/002804 external-priority patent/WO2004003019A2/en
Priority claimed from PCT/GB2004/002829 external-priority patent/WO2004081026A2/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of ZA200610474B publication Critical patent/ZA200610474B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
ZA200610474A 2002-12-27 2006-12-13 Compositions and methods for treating inflammatory disorders ZA200610474B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0230202A GB0230202D0 (en) 2002-12-27 2002-12-27 Ligand
PCT/GB2003/002804 WO2004003019A2 (en) 2002-06-28 2003-06-30 Immunoglobin single variant antigen-binding domains and dual-specific constructs
PCT/GB2004/002829 WO2004081026A2 (en) 2003-06-30 2004-06-30 Polypeptides

Publications (1)

Publication Number Publication Date
ZA200610474B true ZA200610474B (en) 2009-09-30

Family

ID=9950454

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610474A ZA200610474B (en) 2002-12-27 2006-12-13 Compositions and methods for treating inflammatory disorders

Country Status (3)

Country Link
CN (1) CN1745102A (en)
GB (1) GB0230202D0 (en)
ZA (1) ZA200610474B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144573A2 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Multimerization technologies
WO2016097313A1 (en) * 2014-12-19 2016-06-23 Ablynx N.V. Cysteine linked nanobody dimers
SG11201807176XA (en) 2016-03-11 2018-09-27 Scholar Rock Inc TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
AU2018205231A1 (en) * 2017-01-06 2019-07-18 Scholar Rock, Inc. Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
CN111701580B (en) * 2019-12-26 2022-02-15 华中科技大学 Middle molecular toxin adsorbent for removing beta 2 microglobulin in blood

Also Published As

Publication number Publication date
GB0230202D0 (en) 2003-02-05
CN1745102A (en) 2006-03-08

Similar Documents

Publication Publication Date Title
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
IL180187A0 (en) Compositions and methods for treating inflammatory disorders
GB2421434B (en) Compositions And Methods For Treating Gynaecological Disorders
HK1098383A1 (en) Compositions and methods for treating coagulation related disorders
HK1101140A1 (en) Compositions and methods for treating neurological disorders
EP1680009A4 (en) Compositions and methods for diagnosing and treating mental disorders
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1651164A4 (en) Composition and method for treating neurological disorders
IL162838A0 (en) Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
EP1545578A4 (en) Compositions and methods for treating cardiovascular disease
IL179766A0 (en) Compositions and methods using same for treating neurodegenerative disorders
AU2003287443A8 (en) Compositions and methods for pain reduction
EP1567198A4 (en) Materials and methods for treating ocular-related disorders
AU2003212850A8 (en) Methods and compositions for treating cardiovascular disease
EP1478438A4 (en) Methods and compositions for the treatment of asthma and related disorders
AU2003297573A8 (en) Compositions and methods for treating transplants
AU2003247303A1 (en) Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
ZA200610474B (en) Compositions and methods for treating inflammatory disorders
EP1573039A4 (en) Compositions and methods for diagnosing and treating mood disorders
AU2003214920A8 (en) Methods and compositions for treating hematological disorders
AU2003228356A8 (en) Methods and compositions for preventing obesity and obesity related disorders
AU2003275433A8 (en) Compositions and methods for treating pain
AU2003291730A8 (en) Methods and compositions for treating neurodegenerative diseases
EP1844009A4 (en) Compositions and methods for treating cardiovascular disorders
AU2003297259A8 (en) Methods and compositions for treating neurological disorders